|
|||||
|
|
Alteration in PI3K/mTOR,MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma |
|
| Authors: | Haider Mahdi MD Joanne Xiu PhD Sandeep K. Reddy MD Robert DeBernardo MD |
| Affiliation: | 1. Gynecologic Oncology division, Ob/Gyn and Women's Health Institute, Cleveland Clinic, Cleveland, Ohio;2. CARIS Life Sciences, Phoenix, Arizona |
| Abstract: | |
| Keywords: | uterine papillary serous carcinoma serous ovarian carcinoma molecular profile PI3K/AKT/mTOR BRCA HER2/neu CARIS |